
Validea's guru fundamental report indicates that Abbott Laboratories (ABT) receives a 94% rating based on their Twin Momentum Investor model, which is derived from the Dashan Huang's investment strategy combining fundamental and price momentum. The model, which identifies companies with improving fundamentals, suggests strong interest in ABT due to its underlying fundamentals and valuation. Huang's research demonstrated that combining fundamental momentum with price momentum doubled market outperformance.
Abbott Laboratories (ABT), a large-cap growth stock in the Medical Equipment & Supplies industry, has received a notably high rating of 94% from Validea's Twin Momentum Investor model. This model, based on Dashan Huang's published strategy, identifies stocks exhibiting a combination of strong fundamental momentum and price momentum. A score above 90% typically indicates strong interest from this particular strategy. The report confirms that ABT meets the criteria for Fundamental Momentum, Twelve Minus One Momentum, and passes the Final Rank. Huang's research, which underpins this model, demonstrated that stocks ranking in the top 20% for fundamental momentum (a composite measure of seven variables including earnings, ROE, ROA, and profitability ratios) outperformed the market, and this outperformance doubled when combined with price momentum. The overwhelmingly positive sentiment score of 0.8 for ABT further supports this model-driven positive outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment